Head to Head Contrast: Grace Therapeutics (GRCE) and Its Rivals

Grace Therapeutics (NASDAQ:GRCE) is one of 1,072 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Grace Therapeutics to related businesses based on the strength of its risk, dividends, earnings, valuation, institutional ownership, analyst recommendations and profitability.

Risk and Volatility

Grace Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Grace Therapeutics’ rivals have a beta of 3.64, meaning that their average stock price is 264% more volatile than the S&P 500.

Valuation & Earnings

This table compares Grace Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Grace Therapeutics	N/A	-$12.85 million	-1.99
Grace Therapeutics Competitors	$9.93 billion	$136.87 million	-7.35

Grace Therapeutics’ rivals have higher revenue and earnings than Grace Therapeutics. Grace Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 44.0% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 13.5% of Grace Therapeutics shares are held by company insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Grace Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-20.10%	-17.10%
Grace Therapeutics Competitors	-3,399.87%	-235.11%	-32.77%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Grace Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	0	0	1	0	3.00
Grace Therapeutics Competitors	8376	22218	50369	1347	2.54

Grace Therapeutics currently has a consensus target price of $12.00, indicating a potential upside of 419.48%. As a group, “Pharmaceutical preparations” companies have a potential upside of 216.30%. Given Grace Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Grace Therapeutics is more favorable than its rivals.

Summary

Grace Therapeutics beats its rivals on 7 of the 13 factors compared.

About Grace Therapeutics

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.